Publications by authors named "Dewei She"

Claim this Profile
S
Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
Bruce A C Cree, Ho Jin Kim, Brian G Weinshenker, Sean J Pittock, Dean M Wingerchuk, Dewei She

Lancet Neurol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial.
Cory Perugino, Emma L Culver, Arezou Khosroshahi, Wen Zhang, Emanuel Della-Torre, Dewei She

Rheumatol Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism.
Ho Jin Kim, Orhan Aktas, Kristina R Patterson, Schaun Korff, Amy Kunchok, Brian G Weinshenker, Dewei She

Ann Clin Transl Neurol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
Orhan Aktas, Hans-Peter Hartung, Michael A Smith, William A Rees, Kazuo Fujihara, Brian G Weinshenker, Dewei She

J Neurol Neurosurg Psychiatry· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Attack adjudication in neuromyelitis optica spectrum disorder: Substantiation of criteria by magnetic resonance imaging and biomarkers in N-MOmentum.
Brian G Weinshenker, Dean M Wingerchuk, Ari J Green, Jeffrey L Bennett, Ho Jin Kim, Dewei She

Mult Scler· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.
Jeffrey L Bennett, Orhan Aktas, William A Rees, Michael A Smith, Michele Gunsior, Dewei She, Brian G Weinshenker

EBioMedicine· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacodynamic modelling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders.
Li Yan, Bing Wang, Dewei She, Ben Mitchell, Ryan Criste

Br J Clin Pharmacol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results and phase 2b design.
Marc P Bonaca, Richard T George, David A Morrow, Brian A Bergmark, Jeong-Gun Park, Dewei She

Eur Heart J Cardiovasc Pharmacother· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial.
Mary Rensel, Aram Zabeti, Maureen A Mealy, Daniel Cimbora, Dewei She

Mult Scler· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study.
Eoin P Flanagan, Michael Levy, Eliezer Katz, Daniel Cimbora, Jorn Drappa, Dewei She

Mult Scler Relat Disord· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
Romain Marignier, Sean J Pittock, Friedemann Paul, Ho Jin Kim, Jeffrey L Bennett, Brian G Weinshenker, Dewei She

Mult Scler Relat Disord· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
Bruce Ac Cree, Jeffrey L Bennett, Ho Jin Kim, Brian G Weinshenker, Sean J Pittock, Dewei She

Mult Scler· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MEDI6012: Recombinant Human Lecithin Cholesterol Acyltransferase, High-Density Lipoprotein, and Low-Density Lipoprotein Receptor-Mediated Reverse Cholesterol Transport.
Richard T George, Liron Abuhatzira, Susan M Stoughton, Sotirios K Karathanasis, Dewei She

J Am Heart Assoc· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
Orhan Aktas, Michael A Smith, William A Rees, Jeffrey L Bennett, Dewei She

Ann Neurol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.
Romain Marignier, Jeffrey L Bennett, Ho Jin Kim, Brian G Weinshenker, Sean J Pittock, Dewei She

Neurol Neuroimmunol Neuroinflamm· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Bruce A C Cree, Jeffrey L Bennett, Ho Jin Kim, Brian G Weinshenker, Sean J Pittock, Dewei She

Lancet· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial.
Eric L Simpson, Jane R Parnes, Dewei She, Sarah Crouch, William Rees

J Am Acad Dermatol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers.
Paul Baverel, Dewei She, Edward Piper, Shinya Ueda, Tomoko Yoshioka

Drug Metab Pharmacokinet· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis.
Joseph M Parker, Ian N Glaspole, Lisa H Lancaster, Tarik J Haddad, Dewei She

Am J Respir Crit Care Med· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Anti-IL-13 Treatment on Airway Dimensions in Severe Asthma.
Christopher E Brightling, Lars H Nordenmark, Meena Jain, Edward Piper, Dewei She

Am J Respir Crit Care Med· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing.
Paul G Baverel, Meena Jain, Iwona Stelmach, Dewei She, Balaji Agoram

Br J Clin Pharmacol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
Christopher E Brightling, Pascal Chanez, Richard Leigh, Paul M O'Byrne, Stephanie Korn, Dewei She

Lancet Respir Med· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy assessment of two new leprosy skin test antigens: randomized double blind clinical study.
Becky L Rivoire, Nathan A Groathouse, Stephen TerLouw, Kapil Dev Neupane, Chaman Ranjit, Dewei She

PLoS Negl Trop Dis· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study.
Christopher E Brightling, Eugene R Bleecker, Reynold A Panettieri, Mona Bafadhel, Dewei She

Lancet Respir Med· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma.
Edward Piper, Christopher Brightling, Robert Niven, Chad Oh, Raffaella Faggioni, Dewei She

Eur Respir J· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis